[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-occlusion":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,73,100,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100330918","iris--desyne-x2-in-the-iris-des-registry-100330918",false,"NCT03588481","IRIS- DESyne X2 in the IRIS-DES Registry","Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS DESyne X2","Inclusion Criteria:\n\n* Age 19 and more\n* Intervention with DeSyne X2 drug-eluting coronary stent\n* Agreed with written informed consent form\n\nExclusion Criteria:\n\n* Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time\n* Life expectancy of 1year and under\n* Cardiac shock","ALL","19 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.",[25,26,27],"Coronary Stenosis","Coronary Occlusion","Coronary Disease",[29,30,31],"PCI","DES","real world","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2018-11-28",{"date":40,"type":21},"2031-12-31",{"name":42,"class":43},"Seung-Jung Park","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100618361","polish-registry-of-percutaneous-coronary-intervention-for-chronic-total-occlusions-100618361","NCT07330622","Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions","Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions (POL-CTO Registry)","POL-CTO","Inclusion Criteria:\n\n* Patients undergoing CTO PCI based on clinical grounds\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Patient's refusal to participate in the registry","18 Years",{"count":20,"type":21},"1 Year","The goal of this observational study is to evaluate the safety, efficacy, and clinical outcomes of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) in patients treated in contemporary clinical practice in Poland.\n\nThe main questions it aims to answer are:\n\n* What are the rates of procedural success and periprocedural complications of CTO PCI in routine clinical practice?\n* How do CTO PCI strategies and techniques, intravascular imaging, different treatment strategies, and mechanical circulatory support affect clinical outcomes?\n* How do clinical outcomes differ among different patient subgroups?\n* Can artificial intelligence-based analysis predict clinical and quality-of-life outcomes after CTO PCI?\n\nPatients undergoing CTO PCI as part of their standard medical care will be prospectively enrolled in a national, multicenter registry, with clinical, procedural, and follow-up data collected to evaluate real-world outcomes.",[26,58],"Percutaneous Coronary Intervention",[60,61,62],"coronary artery disease","percutaneous coronary intervention","coronary chronic total occlusion","2025-12-29",{"date":65,"type":36},"2026-01-09",{"date":67,"type":36},"2025-05-21",{"date":69,"type":21},"2026-06",{"name":71,"class":43},"National Institute of Cardiology, Warsaw, Poland",21,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100583623","antegrade-dissection-and-re-entry-versus-retrograde-strategy-in-cto-pci-100583623","NCT06878729","Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI","Antegrade Dissection and Re-entry Versus Retrograde Strategy in Chronic Total Occlusion Percutaneous Coronary Intervention","ADRENALINE","Inclusion Criteria:\n\n* clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and\u002For documented ischemia or viability)\n* at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography\n* angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators\n* informed consent for participation in the study\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* acute myocardial infarction\n* cardiogenic shock\n* severe valvular disease\n* estimated life expectancy \\\u003C1 year\n* contraindication to PCI\n* contrast allergy\n* positive pregnancy test or breast-feeding\n* native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \\\u003C2 points)\n* lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators",{"count":82,"type":21},74,"INTERVENTIONAL",[85],"NA","The ADRENALINE trial has been designed as a multi-center, prospective randomized study to compare the procedural and periprocedural outcomes of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using antegrade dissection and re-entry (ADR) versus retrograde strategy. Beyond the patient-oriented outcomes, the influence of the studied CTO PCI strategies on the stress levels among interventional cardiologists will be explored.\n\nThe main questions it aims to answer are as follows:\n\n* What is the difference between ADR versus retrograde strategy with regard to total procedure time, the rates of successful guidewire crossing and periprocedural complications as well as stress levels experienced by interventional cardiologists?\n* Is retrograde approach associated with higher rates of myocardial injury\u002Finfarction based on cardiac troponin\u002Fcardiac magnetic resonance (CMR) as compared with ADR?\n\nParticipants will undergo pre- and postprocedural laboratory testing (cardiac troponin, CK-MB), CMR for late gadolinium enhancement and health status assessment. Subjects undergoing successful CTO PCI using antegrade wiring strategy will be included in the observational arm.",[88,26,58],"Coronary Artery Disease",[60,61,62,90,91],"antegrade dissection and re-entry","retrograde strategy",{"date":93,"type":36},"2026-01-02",{"date":95,"type":36},"2025-07-28",{"date":97,"type":21},"2028-09-30",{"name":71,"class":43},3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":108,"enrollmentInfo":109,"targetDuration":111,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100559566","a-maajor-radiation-based-pci-study-in-stemi-and-nstemi-100559566","NCT06565793","A MAajor RAdiation-based PCI Study in STEMI and NSTEMI","The Impact of Radiation Delivered to the Patient and the Amount of Iodinated Contrast Medium Injected in Complex Versus Noncomplex Percutaneous Coronary Intervention.","MARAA","Inclusion Criteria:\n\n* The patient presents with a STEMI or NSTEMI requiring either a non-complex or complex PCI.\n\nExclusion Criteria:\n\n\\-","90 Years",{"count":110,"type":21},15630,"5 Years","In France and Italy, approximately 240,000 percutaneous coronary angioplasties (PCI) are performed annually, with an increasing number of complex procedures, including those involving the left coronary common trunk, a bifurcation, chronic occlusion, or requiring Rotablator Rotary Atherectomy (ARota). The medical literature lacks sufficient data regarding several key aspects of complex angioplasty. These include the epidemiological characteristics of patients undergoing such procedures, the impact of irradiation delivered and the quantity of iodine injected on these lengthy procedures, their procedural complication rate, and in-hospital mortality.",[114,115,25,116,117,26,118,88],"Myocardial Infarction (MI)","Radiation Toxicity","Coronary Thrombosis","Coronary Artery Calcification","Coronary Syndrome",[120],"PCI,DES, Radiation","NOT_YET_RECRUITING","2024-12-21",{"date":124,"type":36},"2024-12-27",{"date":126,"type":21},"2025-03-01",{"date":128,"type":21},"2025-12-31",{"name":130,"class":43},"Centre Cardiologique du Nord",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":17,"minAge":53,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":83,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100557767","phase-2-pbm-as-strategy-to-cabg-anemic-patients-bypass-graft-cabg-100557767","NCT06542393","PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)","Patient Blood Manegement (PBM) as Perioperative Strategy to Anemic Patients Who Will be Submitted to Coronary Artery Bypass Graft (CABG).","Inclusion Criteria:\n\n* Eletive surgery;\n* Only CABG as procedure;\n* Off pump CABG candidate.\n\nExclusion Criteria:\n\n* Age \\> 80 years;\n* Chronic dialytic kidney disease;\n* Chronic rheumatologic disease;\n* Men with Hb levels \\> 13 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Women with Hb levels \\> 12 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Presence of another heart disease requiring surgical intervention;\n* Presence of hepatic insufficiency;\n* Presence of any implantable electronic cardiac device in any cardiac chambers;\n* Pregnancy;\n* Diagnosis of malignant neoplasia;\n* Thrombophilias;\n* Need for Erythropoietin treatment due to any other disease.\n* Recent ischemic event (\\\u003C 3 months).\n* Ejection fraction \\\u003C30%.",true,"80 Years",{"count":141,"type":21},120,[143],"PHASE2","Anemia poses risks during coronary artery bypass grafting (CABG), increasing complications and mortality rates. Blood transfusions in cardiac surgery have negative outcomes, prompting the use of erythropoietin in Patient Blood Management (PBM) to limit transfusion needs and enhance postoperative recovery. EPO can reduce blood component requirements, adverse events, and inflammation in anemic CABG patients. A study aims to minimize transfusions through a PBM anemia treatment protocol for CABG patients, comparing outcomes in three groups: a Control Group (CG), a Non-PBM Group (NPBMG) treated with blood components, and a PBM Group (GPBM) treated with EPO. Parameters include post-op stay, mortality, cardiovascular events, non-cardiovascular events, ICU time, mechanical ventilation duration, vasoactive drug use, inflammatory responses, and cardiac cell death. Analysis will consider demographic and clinical factors, with expectations that GPBM will yield superior results compared to NPBMG and similar or better outcomes than CG.",[146,27,88,25,26,147,148,149],"Anemia","Systemic Inflammatory Response","Bleeding","Epigenetic Disorder","2024-08-04",{"date":152,"type":36},"2024-08-07",{"date":154,"type":36},"2024-06-01",{"date":156,"type":21},"2026-06-01",{"name":158,"class":43},"Federal University of São Paulo",1]